164472-98-4

Upstream product

• 1122-99-2 2-cyclopentylacetyl chloride 
• 100-51-6 benzyl alcohol 
• 1123-00-8 2-cyclopentylacetic acid 
• 5660-81-1 2-cyclopentylpropanedioic acid 

Downstream Products

• 179537-91-8 10-iodo-2-[(R,S)-cyclopentyl]decanoic acid benzyl ester 
• 929557-07-3 benzyl 2-cyclopentyl-2-hydroxyacetate 
• 929556-35-4 benzyl 2-keto-2-cyclopentylacetate 
• 1420039-31-1 3-cyclopentyl-4-(cis-4-hydroxycyclohexyl)furan-2,5-dione 
• 1420039-29-7 3-(cis-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-4-cyclopentylfuran-2,5-dione 
• 179538-25-1 2-cyclopentyldecan-1,10-dioic acid-1-benzyl-10-t-butyl ester 

Relevant academic research and scientific papers

Proteasome inhibitors for cancer therapy

Proteasome, a large multicatalytic proteinase complex that plays an important role in processing of proteins, has been shown to possess multiple catalytic activities. Among its various activities, the 'chymotrypsin-like' activity of proteasome has emerged as the focus of drug discovery efforts in cancer therapy. Herein we report chiral boronate derived novel, potent, selective and cell-permeable peptidomimetic inhibitors 6 and 7 that displayed activity against various rodent and human tumor cell lines (in vitro).

NDM INHIBITOR

An objective of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of β-lactam antibiotics that have been inactivated as a result of decomposition by NDM. According to the present invention, there is provided an NDM inhibitor contains a compound represented by general formula (I):

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

Multicatalytic protease inhibitors

Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: STR1 Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.

MULTICATALYTIC PROTEASE INHIBITORS

Disclosed herein are inbibitors of the multicatalytic protease enzyme which are represented by the general formula: STR1 Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.